黑料吃瓜群网

Experts are calling for a national register of cost-effective medicines for public hospitals as medical advances push up the cost of the Pharmaceutical Benefits Scheme (PBS).
University of Queensland聽 said expensive new treatments posed a challenge for the health system.
鈥淓ach hospital has a formulary or register of drugs that can be used, but deciding whether to add an expensive new drug is problematic because hospital budgets are capped,鈥� he said.
鈥淒ecisions across Australia are haphazard and access to drugs might depend on where a patient lives.
鈥淭he annual cost of the PBS rose from $6 billion in 2005 to $9.15 billion in 2014 鈥� an increase of just over 50 per cent,鈥� Dr Denaro said.
鈥淥ver the same time the cost of those programs within the PBS which subsidise the most expensive drugs doubled.鈥�
Dr Denaro said the increase in costs had largely been driven by expensive new biological therapies, antivirals for HIV and hepatitis C, and molecules used to treat some cancers.
鈥淚t is encouraging that medical advances are producing innovative new treatments but incredibly challenging to find funding while not re-allocating resources from other areas of health care,鈥� he said.
, Chair of Clinical Pharmacology at the University of Newcastle, said more surveillance was required to assess the clinical outcomes of new drugs.
鈥淒rug companies are less likely to fund definitive trials once the drug is on the market,鈥� Professor Martin said.
鈥淭here needs to be funding for independent assessment 鈥� and those drugs that don鈥檛 live up to their initial promise should be considered for removal from the PBS.鈥�
Professor Martin and Dr Denaro are recommending an electronic national register for all Australian hospitals, funded by the Commonwealth and regularly updated by a national committee.
鈥淭his would improve decision-making and 鈥�